Search Results - "KONICEK, Bruce W"

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes by Gkogkas, Christos G, Khoutorsky, Arkady, Cao, Ruifeng, Jafarnejad, Seyed Mehdi, Prager-Khoutorsky, Masha, Giannakas, Nikolaos, Kaminari, Archontia, Fragkouli, Apostolia, Nader, Karim, Price, Theodore J, Konicek, Bruce W, Graff, Jeremy R, Tzinia, Athina K, Lacaille, Jean-Claude, Sonenberg, Nahum

“…Fragile X syndrome (FXS) is the leading genetic cause of autism. Mutations in Fmr1 (fragile X mental retardation 1 gene) engender exaggerated translation…”
Get full text

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy by GRAFF, Jeremy R, KONICEK, Bruce W, CARTER, Julia H, MARCUSSON, Eric G

“…The eukaryotic translation initiation factor 4E (eIF4E) is frequently overexpressed in human cancers in relation to disease progression and drives cellular…”
Get full text

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors by Altman, Jessica K., Szilard, Amy, Konicek, Bruce W., Iversen, Philip W., Kroczynska, Barbara, Glaser, Heather, Sassano, Antonella, Vakana, Eliza, Graff, Jeremy R., Platanias, Leonidas C.

“…Mnk kinases regulate the phosphorylation and activation of the eukaryotic initiation factor 4E (eIF4E), a protein that plays key roles in the initiation of…”
Get full text

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO) by Armstrong, April W, Riedl, Elisabeth, Brunner, Patrick M, Piaserico, Stefano, Visser, Willie I, Haustrup, Natalie, Konicek, Bruce W, Kadziola, Zbigniew, Nunez, Mercedes, Brnabic, Alan, Schuster, Christopher

“…Despite the abundance of data concerning biologic treatments for patients with psoriasis, clinicians are often challenged with discerning the optimal treatment…”
Get full text

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity by Graff, Jeremy R, Konicek, Bruce W, Vincent, Thomas M, Lynch, Rebecca L, Monteith, David, Weir, Spring N, Schwier, Phil, Capen, Andrew, Goode, Robin L, Dowless, Michele S, Chen, Yuefeng, Zhang, Hong, Sissons, Sean, Cox, Karen, McNulty, Ann M, Parsons, Stephen H, Wang, Tao, Sams, Lillian, Geeganage, Sandaruwan, Douglass, Larry E, Neubauer, Blake Lee, Dean, Nicholas M, Blanchard, Kerry, Shou, Jianyong, Stancato, Louis F, Carter, Julia H, Marcusson, Eric G

“…Expression of eukaryotic translation initiation factor 4E (eIF4E) is commonly elevated in human and experimental cancers, promoting angiogenesis and tumor…”
Get full text

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases by KONICEK, Bruce W, STEPHENS, Jennifer R, MCCANN, Denis J, PELLETIER, Jerry, FURIC, Luc, YINGLING, Jonathan M, STANCATO, Louis F, SONENBERG, Nahum, GRAFF, Jeremy R, MCNULTY, Ann M, ROBICHAUD, Nathaniel, PEERY, Robert B, DUMSTORF, Chad A, DOWLESS, Michele S, IVERSEN, Philip W, PARSONS, Stephen, ELLIS, Karen E

“…Activation of the translation initiation factor 4E (eIF4E) promotes malignant transformation and metastasis. Signaling through the AKT-mTOR pathway activates…”
Get full text

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors by Konicek, Bruce W, Capen, Andrew R, Credille, Kelly M, Ebert, Philip J, Falcon, Beverly L, Heady, Gary L, Patel, Bharvin K R, Peek, Victoria L, Stephens, Jennifer R, Stewart, Julie A, Stout, Stephanie L, Timm, David E, Um, Suzane L, Willard, Melinda D, Wulur, Isabella H, Zeng, Yi, Wang, Yong, Walgren, Richard A, Betty Yan, Sau-Chi

“…Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib…”
Get full text

Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide by Jacobson, Blake A, Thumma, Saritha C, Jay-Dixon, Joseph, Patel, Manish R, Dubear Kroening, K, Kratzke, Marian G, Etchison, Ryan G, Konicek, Bruce W, Graff, Jeremy R, Kratzke, Robert A

“…Aberrant cap-dependent translation is implicated in tumorigenesis in multiple tumor types including mesothelioma. In this study, disabling the eIF4F complex by…”
Get full text

Targeting the eIF4F translation initiation complex for cancer therapy by Konicek, Bruce W., Dumstorf, Chad A., Graff, Jeremy R.

“…Abstract In multiple human cancers, the function of the eukaryotic translation initiation factor 4E (eIF4E) is elevated and directly related to disease…”
Get full text

Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis by Dumstorf, Chad A, Konicek, Bruce W, McNulty, Ann M, Parsons, Stephen H, Furic, Luc, Sonenberg, Nahum, Graff, Jeremy R

“…Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin…”
Get full text

AKT-1, -2, and -3 are Expressed in Both Normal and Tumor Tissues of the Lung, Breast, Prostate, and Colon by ZINDA, Michael J, JOHNSON, Mac A, GRAFF, Jeremy R, PAUL, Jonathan D, HORN, Candice, KONICEK, Bruce W, LU, Zhao Hai, SANDUSKY, George, THOMAS, James E, NEUBAUER, Blake Lee, LAI, Mei T

“…Purpose: The AKT/PKB kinase controls many of the intracellular processes that are dysregulated in human cancer, including the suppression of apoptosis and…”
Get full text

Expression of Group IIa Secretory Phospholipase A2 Increases with Prostate Tumor Grade by GRAFF, Jeremy R, KONICEK, Bruce W, DEDDENS, James A, CHEDID, Marcio, HURST, Bernadette M, COLLIGAN, Bruce, NEUBAUER, Blake Lee, CARTER, Harry W, CARTER, Julia H

“…Purpose: Arachidonate release contributes to prostate tumor progression as arachidonate is metabolized into prostaglandins and leukotrienes, potent mediators…”
Get full text

Integrin-linked Kinase Expression Increases with Prostate Tumor Grade by GRAFF, Jeremy R, DEDDENS, James A, KONICEK, Bruce W, COLLIGAN, Bruce M, HURST, Bernadette M, CARTER, Harry W, CARTER, Julia H

“…Purpose: Integrin-linked kinase (ILK) overexpression can suppress anoikis, promote anchorage-independent cell cycle progression, and induce tumorigenesis and…”
Get full text

IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis by Ochsner, Scott A., Pedroza, Mesias, Pillich, Rudolf T., Krishnan, Venkatesh, Konicek, Bruce W., Dow, Ernst R., Park, So Young, Agarwal, Sandeep K., McKenna, Neil J.

“…Unbiased informatics approaches have the potential to generate insights into uncharacterized signaling pathways in human disease. In this study, we generated…”
Get full text

Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas by Gottlieb, Alice B, Armstrong, April, Blauvelt, Andrew, Griffiths, Christopher E M, Pinter, Andreas, Gooderham, Melinda, Lomaga, Mark, Burge, Russel T, Konicek, Bruce W, McDonald, Meghan Feely, See, Kyoungah, McKean-Matthews, Missy, Mabuchi, Tomotaka

“…Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects…”
Get more information

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping by Yan, S. Betty, Um, Suzane L., Peek, Victoria L., Stephens, Jennifer R., Zeng, Wei, Konicek, Bruce W., Liu, Ling, Manro, Jason R., Wacheck, Volker, Walgren, Richard A.

“…Summary Purpose Approximately 3% of lung cancer bears mutations leading to MET exon 14 skipping, an oncogenic driver which is further evidenced by case reports…”
Get full text

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models by Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.

“…Summary The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell…”
Get full text

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival by GRAFF, Jeremy R, KONICEK, Bruce W, HURST, Bernadette M, DEDDENS, James A, NEUBAUER, Blake L, STANCATO, Louis F, CARTER, Harry W, DOUGLASS, Larry E, CARTER, Julia H, LYNCH, Rebecca L, DUMSTORF, Chad A, DOWLESS, Michele S, MCNULTY, Ann M, PARSONS, Stephen H, BRAIL, Leslie H, COLLIGAN, Bruce M, KOOP, Jonathan W

“…Elevated eukaryotic translation initiation factor 4E (eIF4E) function induces malignancy in experimental models by selectively enhancing translation of key…”
Get full text

The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts by GRAFF, Jeremy R, MCNULTY, Ann M, SAMS, Lillian, HUSS, Karen L, CAMPBELL, Robert M, IVERSEN, Philip W, NEUBAUER, Blake Lee, BROWN, Thomas J, MUSIB, Luna, GEEGANAGE, Sandaruwan, THORNTON, Donald, ROSS HANNA, Kimberly, KONICEK, Bruce W, LYNCH, Rebecca L, BAILEY, Spring N, BANKS, Crystal, CAPEN, Andrew, GOODE, Robin, LEWIS, Jason E

“…Abstract Activation of protein kinase Cβ (PKCβ) has been repeatedly implicated in tumor-induced angiogenesis. The PKCβ-selective inhibitor, Enzastaurin…”
Get full text

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry by Lockshin, Benjamin, Harrison, Ryan W., McLean, Robert R., Crabtree, Margaux M., Konicek, Bruce W., Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Burge, Russel T.

“…Introduction The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and…”
Get full text